Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Inclusion Criteria: * 18 years or older * Diagnosis of MDS or CMML * Diagnosis of AML, Multiple myeloma, Hodgkin's or Non-Hodgkin's lymphoma for whom standard curative or palliative measures do not exist or are no longer effective * ECOG Performance Status 0-2 * Use of acceptable birth control * Standard safety inclusion for serum creatinine, AST, ALT, bilirubin * Serum bicarbonate greater than or equal to 20 mEq/L * Platelet count greater than or equal to 25,000/uL * Hemoglobin greater than or equal to 500/uL * Signed informed consent Exclusion Criteria: * Diagnosis of acute promyelocytic leukemia * Treatment with demethylating agents within 21 days prior to Cycle 1, Day 1 * Treatment with any anticancer therapy (standard or investigational) within 21 days prior to Cycle 1, Day 1 or ongoing adverse events from previous treatment * Hypersensitivity to azacitidine or mannitol * Active, uncontrolled infection * Presence of GI disease, malignant tumors or other conditions known to interfere with ADME * Known or active HIV, viral hepatitis B or C * Breastfeeding or pregnant females * Current or uncontrolled cardiac disease